HTBX
Top-News
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
... 160 161 163 164 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter ... 160 161 163 164 ...
Heat Biologics - 3 Krebsmittel in der Pipeline!
Beiträge: 4.380
Zugriffe: 1.030.135 / Heute: 226
Zugriffe: 1.030.135 / Heute: 226
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +72,94%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +55,51%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +38,10%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +37,57%
Konso aber das wird wieder, auch wenn es etwas übertrieben war
www.channelnewsasia.com/news/...r-a-covid-19-vaccine-12978536
Impfstoff wird an Probanden getestet. Mal schauen wann die Nachricht rausgehauen wird. Dann sind hier wieder 100% garantiert.
www.sec.gov/Archives/edgar/data/1476963/...x-20200630x10q.htm
gestern hätte ich es verstanden, aber warum heute?
haben die jedenfalls geschickt für sich nutzen können.
Cash Bestände sind wieder aufgefüllt. mal sehen, was die Krebspipeline die kommenden Monate zu Tage fördert.......
Cash Bestände sind wieder aufgefüllt. mal sehen, was die Krebspipeline die kommenden Monate zu Tage fördert.......
Sounds Good :-)
Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies
T cell driven immune response achieved with just a single dose
Potential to be used in combination with other COVID-19 vaccine approaches
DURHAM, NC / ACCESSWIRE / August 13, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported preclinical data for Heat's gp96-based COVID-19. The data, generated at the University of Miami Miller School of Medicine, shows robust T cell mediated immune response directed against the spike protein of SARS-CoV-2.
Heat Biologics' COVID-19 vaccine induced the expansion of both "killer" CD8+ T cells that destroy virus infected cells, as well as "helper" CD4+ T cells that assist in producing highly specific antibodies. Both T cell subsets were shown to release cytokines that amplify the anti-viral immune response and, upon vaccination, memory CD8+ T cells migrated to the lungs and airways-the tissue-specific site of interest for SARS-CoV-2 infection. These lung and airway tissue resident memory CD8+ T cells are crucial in mounting an effective response to respiratory viruses.
Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine and co-developer of Heat's gp96 platform, commented, "We are highly encouraged by the animal data generated around the COVID-19 vaccine and we look forward to publishing the full details of this study in the coming weeks. Specifically, we noted several important immune responses generated by the vaccine against SARS-CoV-2 after a single injection, including SARS-CoV-2 specific CD8+ and CD4+ T cells in the lungs and airways."
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We are encouraged by the progress being made by other companies developing vaccines against COVID-19. However, unlike most of these approaches that drive primarily an antibody response, our COVID-19 vaccine is designed to drive predominantly T cell immunity along with antibody responses and innate immunity. As a result, we believe our vaccine has the potential to be used as either a standalone vaccine, or in combination with these other approaches to enhance efficacy. I appreciate the tremendous support of Dr. Strbo and her team at the University of Miami, as well as the team at Heat who have worked around the clock given the urgency of the pandemic. We look forward to providing further updates as soon as possible."
Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies
T cell driven immune response achieved with just a single dose
Potential to be used in combination with other COVID-19 vaccine approaches
DURHAM, NC / ACCESSWIRE / August 13, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported preclinical data for Heat's gp96-based COVID-19. The data, generated at the University of Miami Miller School of Medicine, shows robust T cell mediated immune response directed against the spike protein of SARS-CoV-2.
Heat Biologics' COVID-19 vaccine induced the expansion of both "killer" CD8+ T cells that destroy virus infected cells, as well as "helper" CD4+ T cells that assist in producing highly specific antibodies. Both T cell subsets were shown to release cytokines that amplify the anti-viral immune response and, upon vaccination, memory CD8+ T cells migrated to the lungs and airways-the tissue-specific site of interest for SARS-CoV-2 infection. These lung and airway tissue resident memory CD8+ T cells are crucial in mounting an effective response to respiratory viruses.
Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine and co-developer of Heat's gp96 platform, commented, "We are highly encouraged by the animal data generated around the COVID-19 vaccine and we look forward to publishing the full details of this study in the coming weeks. Specifically, we noted several important immune responses generated by the vaccine against SARS-CoV-2 after a single injection, including SARS-CoV-2 specific CD8+ and CD4+ T cells in the lungs and airways."
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented, "We are encouraged by the progress being made by other companies developing vaccines against COVID-19. However, unlike most of these approaches that drive primarily an antibody response, our COVID-19 vaccine is designed to drive predominantly T cell immunity along with antibody responses and innate immunity. As a result, we believe our vaccine has the potential to be used as either a standalone vaccine, or in combination with these other approaches to enhance efficacy. I appreciate the tremendous support of Dr. Strbo and her team at the University of Miami, as well as the team at Heat who have worked around the clock given the urgency of the pandemic. We look forward to providing further updates as soon as possible."
Bekommen sie von der Regierung oder barda u.s.w. finanzielle Unterstützung für die weitere Phasen des impfstoffes, oder haben das beantragt? Weiß jemand mehr? Danke
The System for Award Management (SAM) is an official website of the U.S. government. There is no cost to use SAM. You can use this site for FREE to:
-Register to do business with the U.S. government
-Update or renew your entity registration
-Check status of an entity registration
-Search for entity registration and exclusion records
Unter Search records im Feld Quick Search Heat Biologics eintragen und suchen lassen oder diese Nummer hier 828572292 unter DUNS number Search eingeben.
-Register to do business with the U.S. government
-Update or renew your entity registration
-Check status of an entity registration
-Search for entity registration and exclusion records
Unter Search records im Feld Quick Search Heat Biologics eintragen und suchen lassen oder diese Nummer hier 828572292 unter DUNS number Search eingeben.
www.sam.gov/SAM/pages/public/entitySearch/...veExclusions.jsf
28.6 nur noch abwärts, immer nur alte Artikel Posten bringt nichts. Die sollen sich auf HS-110 konzentrieren. Meiner Meinung Nach sind die beim Impfstoff viel zu langsam.
Ich denke ohne Funding geht es hier nur langsam voran.
sieht es so aus als wenn es ein einziger Coronapush gewesen ist. Dauert nicht mehr lange und wir sehen den 1USD wieder. Wo bleibt die Finanzierung und ein Partner, nichts in Sicht. Bisher alles nur heiße Luft.
hier haben heute einige Jungs richtig Geld gemacht. Short Quote über 50%
(Verkleinert auf 81%) 
Wundert mich, dass es jetzt erst passiert.
Also sehen wir den $ wohl bald schon wieder von unten.
Also sehen wir den $ wohl bald schon wieder von unten.
|
Neueste Beiträge aus dem Scorpius Holdings Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
8 | 4.379 | Heat Biologics - 3 Krebsmittel in der Pipeline! | Balu4u | Highländer49 | 08.03.24 13:53 | |
| 2 | Face the Heat | VEB Plaste und Ela. | Advamillionär | 24.04.21 23:58 |
